Fund IV’s limited partners include endowments, foundations, insurance companies, state and corporate pension plans, fund of funds and large family offices.
Our portfolio companies generate revenues of over .0 billion annually and employ approximately 9,000 people.
New York, July 20, 2016 - SK Capital, a private investment firm with a disciplined focus on the specialty materials, chemicals and healthcare sectors, announced a new organizational structure and additions to the senior management team of the firm’s recently acquired specialty active pharmaceutical ingredient (“API”) and raw materials businesses, Noramco Inc. Matthew Martin, who was previously the General Manager for the recently acquired businesses has been appointed CEO. Martin will be supported by a management team comprised of senior executives that are transitioning with the businesses as well as an influx of new, highly-experienced talent.
Our integrated, multi-disciplinary team utilizes its industry, operating and investment experience to help transform businesses into higher performing organizations.
Located in New York, NY and Boca Raton, FL, the firm has over .5 billion in third party capital under management.
“Our combination of deep industry and operating experience in our sectors of focus, differentiated deal flow, and proven ability to drive improvement in portfolio companies resonated with investors as they seek outsized returns in a competitive and volatile marketplace.” He added, “Consistent with prior funds, Fund IV will have a significant commitment from the general partner, further aligning our interests with those of our limited partners.” Barry Siadat, Managing Director, remarked, “With a portfolio of companies that generate over billion of annual revenues, SK Capital has established itself as a significant player in the specialty materials, chemicals and healthcare sectors.We have a strong track record of providing creative solutions in corporate carve-outs, creating value both for the sellers of non-core assets as well as in the businesses as they become independent entities.” He added, “We are very appreciative of the confidence shown in us by both our existing investors and the many new, high quality investors that have joined us in Fund IV, and are working hard to reward that faith.” SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and healthcare sectors.